CRVS
Price
$20.84
Change
-$0.50 (-2.34%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
1.79B
29 days until earnings call
Intraday BUY SELL Signals
HIND
Price
$2.57
Change
+$0.50 (+24.15%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
11.91M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRVS vs HIND

Header iconCRVS vs HIND Comparison
Open Charts CRVS vs HINDBanner chart's image
Corvus Pharmaceuticals
Price$20.84
Change-$0.50 (-2.34%)
Volume$24.56K
Capitalization1.79B
Vyome Holdings
Price$2.57
Change+$0.50 (+24.15%)
Volume$4.36K
Capitalization11.91M
CRVS vs HIND Comparison Chart in %
CRVS
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRVS vs. HIND commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Buy and HIND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (CRVS: $21.34 vs. HIND: $2.07)
Brand notoriety: CRVS and HIND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 35% vs. HIND: 43%
Market capitalization -- CRVS: $1.79B vs. HIND: $11.91M
CRVS [@Biotechnology] is valued at $1.79B. HIND’s [@Biotechnology] market capitalization is $11.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 1 FA rating(s) are green whileHIND’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 1 green, 4 red.
  • HIND’s FA Score: 0 green, 5 red.
According to our system of comparison, CRVS is a better buy in the long-term than HIND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while HIND’s TA Score has 4 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 6 bearish.
  • HIND’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, HIND is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а -3.35% price change this week, while HIND (@Biotechnology) price change was -36.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

CRVS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($1.79B) has a higher market cap than HIND($11.9M). CRVS YTD gains are higher at: 177.143 vs. HIND (-39.826). CRVS has more cash in the bank: 65.7M vs. HIND (5.71M). HIND has less debt than CRVS: HIND (38.6K) vs CRVS (1.01M).
CRVSHINDCRVS / HIND
Capitalization1.79B11.9M15,025%
EBITDA-38.76MN/A-
Gain YTD177.143-39.826-445%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash65.7M5.71M1,151%
Total Debt1.01M38.6K2,619%
FUNDAMENTALS RATINGS
CRVS vs HIND: Fundamental Ratings
CRVS
HIND
OUTLOOK RATING
1..100
8995
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
21100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3494
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HIND's Valuation (40) in the null industry is somewhat better than the same rating for CRVS (78) in the Pharmaceuticals Major industry. This means that HIND’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (21) in the Pharmaceuticals Major industry is significantly better than the same rating for HIND (100) in the null industry. This means that CRVS’s stock grew significantly faster than HIND’s over the last 12 months.

CRVS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as HIND (100) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

CRVS's Price Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for HIND (94) in the null industry. This means that CRVS’s stock grew somewhat faster than HIND’s over the last 12 months.

CRVS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as HIND (100) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSHIND
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 13 days ago
86%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WTW335.1018.49
+5.84%
Willis Towers Watson Public Limited
SGC9.97-0.01
-0.10%
Superior Group of Companies
BOLT5.88-0.03
-0.51%
Bolt Biotherapeutics Inc
CWH13.01-0.15
-1.14%
Camping World Holdings
AB41.36-0.52
-1.24%
AllianceBernstein Holding LP

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with ACRS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then ACRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+1.72%
ACRS - CRVS
65%
Loosely correlated
-3.88%
RAPT - CRVS
46%
Loosely correlated
+0.12%
RZLT - CRVS
41%
Loosely correlated
-2.78%
AMLX - CRVS
36%
Loosely correlated
-1.23%
KRRO - CRVS
36%
Loosely correlated
-2.68%
More

HIND and

Correlation & Price change

A.I.dvisor tells us that HIND and CMPX have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIND and CMPX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIND
1D Price
Change %
HIND100%
-5.91%
CMPX - HIND
21%
Poorly correlated
-1.53%
CRVS - HIND
21%
Poorly correlated
+1.72%
ACET - HIND
20%
Poorly correlated
-3.51%
EXOZ - HIND
6%
Poorly correlated
+5.53%
YDES - HIND
4%
Poorly correlated
-5.41%
More